BioCryst Pharmaceuticals Reports Strong Revenue Growth

BioCryst Pharmaceuticals sees impressive revenue growth as it announces a 36% increase in total revenue for 2024, with earnings anticipated to improve by 2026. Investors should watch for potential stock price impacts.

Date: 10-01-2025

AI Rating: 7

Revenue Growth: BioCryst Pharmaceuticals reported a significant increase in total revenue for both the fourth quarter and full year of 2024. The total revenue in the fourth quarter reached $130.8 million, which is a 40% increase from the previous year. For the full year 2024, total revenue was reported at $450 million, a 36% increase compared to the last fiscal year.

Furthermore, the company’s preliminary net revenue from ORLADEYO for full year 2024 stood at $437 million, marking a 34% increase from the previous year, while the fourth quarter revenue for ORLADEYO increased by 36% to $123.5 million. The growth in both total revenue and segment revenue indicates a positive trend, which could lead to increased investor confidence and potentially higher stock prices.

Earnings Per Share (EPS): The company forecasts approaching quarterly positive EPS and positive cash flow in the second half of 2025. It aims for profitability on an EPS basis for the full year 2026. With EPS projected to become positive, this indicates a promising outlook for shareholders, boosting the potential for stock price appreciation.

Free Cash Flow (FCF): BioCryst indicates an expectation of positive cash flow in the second half of 2025 with plans to be profitable for the full year 2026. Positive cash flow is critical for maintaining operations and funding future growth, which is a favorable indicator for investors.

The anticipated revenue growth and positive EPS outlook may encourage investor interest, potentially leading to an upward trajectory in BioCryst's stock price in the coming years.

Stocks: BCRX